Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting

Benzinga Newsdesk www.benzinga.com Neutral 93.3%

Neg 0% Neu 93.3% Pos 0%

https://www.sec.gov/Archives/edgar/data/34956/000119312526417939/d139658dex991.htm

Comments

No comments yet. Be the first!